文献速递头颈与中枢神经肿瘤

帕博利珠单抗治疗铂类和西妥昔单抗难治性头颈癌:一项单臂II期研究结果

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
PubMed 文献 · J Clin Oncol · 2017-03-22

这项单臂II期KEYNOTE-055研究评估了帕博利珠单抗200 mg每3周方案用于铂类和西妥昔单抗治疗失败的复发/转移性头颈鳞癌患者。171例受试者中,总缓解率为16%(95%CI 11%-23%),中位缓解持续时间8个月,中位无进展生存期2.1个月,中位总生存期8个月;64%发生治疗相关不良事件,15%为≥3级。

要点

  • 铂类和西妥昔单抗难治性复发/转移性头颈鳞癌中,帕博利珠单抗总缓解率为16%(95%CI 11%-23%)。
  • 中位缓解持续时间8个月(范围2+至12+个月),分析时75%的缓解仍在持续。
  • 64%发生治疗相关不良事件,15%为≥3级,1例因治疗相关不良事件死亡。

核心结论

  • 帕博利珠单抗在既往接受铂类和西妥昔单抗治疗的复发/转移性头颈鳞状细胞癌中显示出有临床意义的抗肿瘤活性和可接受的安全性。

研究设计与样本

  • 单臂II期KEYNOTE-055研究,纳入铂类和西妥昔单抗治疗失败(铂类和西妥昔单抗治疗后6个月内疾病进展)的复发/转移性头颈鳞状细胞癌患者,共171例接受帕博利珠单抗200 mg每3周治疗,每6至9周进行影像学检查。
  • 主要终点为总缓解率(实体瘤疗效评价标准v1.1,中心 review)和安全性,疗效在所有接受治疗患者及按PD-L1表达和HPV状态划分的亚组中评估。

主要发现

  • 171例接受治疗患者中,75%既往接受过≥2线转移性疾病治疗,82%为PD-L1阳性,22%为HPV阳性。
  • 109例(64%)发生治疗相关不良事件,26例(15%)发生≥3级事件,7例(4%)因治疗相关不良事件中断治疗,1例因治疗相关不良事件死亡。
  • 总缓解率为16%(95%CI 11%-23%),中位缓解持续时间为8个月(范围2+至12+个月),分析时75%的缓解仍在持续。
  • 所有HPV和PD-L1亚组的缓解率相似,中位无进展生存期为2.1个月,中位总生存期为8个月。

关键数值与推荐

  • 总缓解率16%(95%CI 11%-23%),中位缓解持续时间8个月(范围2+至12+个月),75%的缓解在分析时仍在持续。
  • 中位无进展生存期2.1个月,中位总生存期8个月。
  • 治疗相关不良事件发生率64%,≥3级治疗相关不良事件发生率15%,因治疗相关不良事件中断治疗率4%,治疗相关死亡1例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose There are no approved treatments for recurrent/metastatic head and neck squamous cell carcinoma refractory to platinum and cetuximab. In the single-arm, phase II KEYNOTE-055 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum- and cetuximab-pretreated population with poor prognosis. Methods Eligibility stipulated disease progression within 6 months of platinum and cetuximab treatment. Patients received pembrolizumab 200 mg every 3 weeks. Imaging was performed every 6 to 9 weeks. Primary end points: overall response rate (Response Evaluation Criteria in Solid Tumors v1.1, central review) and safety. Efficacy was assessed in all dosed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavirus (HPV) status. Results Among 171 patients treated, 75% received two or more prior lines of therapy for metastatic disease, 82% were PD-L1 positive, and 22% were HPV positive. At the time of analysis, 109 patients (64%) experienced a treatment-related adverse event; 26 patients (15%) experienced a grade ≥ 3 event. Seven patients (4%) discontinued treatment, and one died of treatment-related adverse events. Overall response rate was 16% (95% CI, 11% to 23%), with a median duration of response of 8 months (range, 2+ to 12+ months); 75% of responses were ongoing at the time of analysis. Response rates were similar in all HPV and PD-L1 subgroups. Median progression-free survival was 2.1 months, and median overall survival was 8 months. Conclusion Pembrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in recurrent/metastatic head and neck squamous cell carcinoma previously treated with platinum and cetuximab.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bauml J, Seiwert TY, Pfister DG, et al. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017. PMID: 28328302. doi:10.1200/JCO.2016.70.1524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。